Summary
Bristol-Myers Squibb Company (BMY) reported third quarter and nine-month results for 2014, showing a mixed financial performance characterized by strategic divestitures and growth in key therapeutic areas. Total revenues declined slightly year-over-year for both the quarter and the nine-month period, primarily due to the significant divestiture of the company's diabetes business to AstraZeneca in February 2014. This sale resulted in a substantial gain recognized in the third quarter. Despite the overall revenue decrease, the company saw strong growth in its oncology portfolio, particularly with Opdivo and Yervoy, and its cardiovascular drug Eliquis. The company also experienced challenges in certain therapeutic areas, such as a decline in Virology sales due to generic competition and the withdrawal of a Hepatitis C treatment from U.S. FDA approval consideration. Net earnings attributable to BMS increased for both periods, driven by the gain on the diabetes business sale and effective cost management, including restructuring initiatives. The company ended the period with a robust cash position and continued to manage its debt effectively. Investors should closely monitor the progress of key growth drivers like Opdivo and Eliquis, as well as the impact of ongoing patent expirations and competitive pressures on its mature product portfolio.
Financial Highlights
56 data points| Revenue | $3.92B |
| Cost of Revenue | $1.01B |
| Gross Profit | $2.91B |
| R&D Expenses | $983.00M |
| SG&A Expenses | $1.03B |
| Operating Expenses | $2.91B |
| Interest Expense | $50.00M |
| Net Income | $721.00M |
| EPS (Basic) | $0.43 |
| EPS (Diluted) | $0.43 |
| Shares Outstanding (Basic) | 1.66B |
| Shares Outstanding (Diluted) | 1.67B |
Key Highlights
- 1Total Revenues for the nine months ended September 30, 2014, decreased by 3% to $11.62 billion compared to $11.94 billion in the prior year, largely due to the divestiture of the diabetes business.
- 2Net Earnings Attributable to BMS increased to $1.99 billion for the nine months ended September 30, 2014, up from $1.84 billion in the same period last year, aided by a $539 million gain on the sale of the diabetes business.
- 3Strong growth was observed in key products: Sprycel (dasatinib) up 20% to $1.095 billion, Yervoy (ipilimumab) up 35% to $942 million, and Eliquis (apixaban) revenues significantly increased to $493 million for the nine-month period.
- 4Opdivo (nivolumab), a promising oncology drug, achieved regulatory milestones and positive clinical trial results, with a U.S. FDA decision anticipated in March 2015.
- 5The company divested its diabetes business to AstraZeneca in February 2014, a significant strategic move that impacted overall revenue but generated substantial proceeds and a reported gain.
- 6Research and development expenses increased by 21% to $3.345 billion for the nine months, driven by IPRD impairment charges and acquisition costs for iPierian.
- 7The company maintained a strong liquidity position, with Cash, Cash Equivalents and Marketable Securities totaling $11.55 billion as of September 30, 2014, and a net cash position of $3.88 billion.